Glaukos Obtains $30,000,000 Series F Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a92f7044-dcea-4369-9696-108169d57d64&Preview=1 -
Date
2/8/2013 -
Company Name
Glaukos -
Mailing Address
26051 Merit Circle Laguna Hills, CA 92653 -
Company Description
Glaukos is creating a new class of micro-bypass therapies to achieve sustainable, target intraocular pressures through the restoration of physiologic outflow, reduce the challenges and risks of glaucoma management associated with traditional therapies, and aid in the preservation of vision. -
Website
http://www.glaukos.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series F -
Proceeds Purposes
The funds also will be used for investigational device exemption pivotal registration studies of iStent supra, a suprachoroidal implant, and iStent inject, a second-generation trabecular bypass implant. -
M&A Terms
-
Venture Investor
Meritech Capital Partners -
Venture Investor
Versant Ventures -
Venture Investor
Montreux Equity Partners -
Venture Investor
InterWest Partners -
Venture Investor
Frazier Healthcare Ventures -
Venture Investor
OrbiMed Advisors -
Venture Investor
Gund Investment Corporation -
Venture Investor
Domain Associates
